



Atty. Dkt. No. 034536-0407

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Tod R. SMEAL, et al.

Title: GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF

Appl. No.: 10/611,671

Filing Date: 07/02/2003

Examiner: Unassigned

Art Unit: 1642

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.


The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date 12/31/03

FOLEY & LARDNER  
Customer Number: 22428  
Telephone: (202) 672-5475  
Facsimile: (202) 672-5399

Respectfully submitted,

By



Beth A. Burrous  
Attorney for Applicant  
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

3

## Complete if Known

Application Number	10/611,671
Filing Date	07/02/2003
First Named Inventor	Tod R. SMEAL
Group Art Unit	1642
Examiner Name	Unassigned

Attorney Docket Number 034536-0407

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
O J P E	JUN 05 2004 PATENT & TRADEMARK OFFICE USCA	ABO et al., "PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia," <u>The EMBO Journal</u> , 1998, pp. 6527-6540, Vol. 17, No. 22, Oxford University Press	
	A2	CALLOW et al., "Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines," <u>The Journal of Biological Chemistry</u> , January 4, 2002, pp. 550-558, Vol. 277, No. 1, The American Society for Biochemistry and Molecular Biology, Inc., USA	
	A3	CHAN et al., "Expression cDNA cloning of a novel oncogene with sequence similarity to regulators of small GTP-binding proteins," <u>Oncogene</u> , 1994, pp. 1057-1063, Vol. 9, Macmillan Press Ltd.	
	A4	CRAVCHIK et al., "A novel strategy for the immunological tagging of cDNA constructs," <u>Gene</u> , 1993, pp. 139-143, Vol. 137, Elsevier Science Publishers B.V.	
	A5	DAN et al., "Cytoskeletal Changes Regulated by the PAK4 Serine/Threonine Kinase Are Mediated by LIM Kinase 1 and Cofilin," <u>The Journal of Biological Chemistry</u> , August 24, 2001, pp. 32115-32121, Vol. 276, No. 34, The American Society for Biochemistry and Molecular Biology, Inc., USA	
	A6	DAN et al., "PAK5, a New Brain-Specific Kinase, Promotes Neurite Outgrowth in N1E-115 Cells," <u>Molecular and Cellular Biology</u> , January 2002, pp. 567-577, Vol. 22, No. 2, American Society for Microbiology	
	A7	DEO et al., "Green Fluorescent Protein Mutant as Label in Homogeneous Assays for Biomolecules," <u>Analytical Biochemistry</u> , 2001, pp. 52-59, Vol. 289, Academic Press	
	A8	GAUTHIER-ROUVIÈRE et al., "ras-induced c-fos expression and proliferation in living rat fibroblasts involves C-kinase activation and the serum response element pathway," <u>The EMBO Journal</u> , 1990, pp. 171-180, Vol. 9, No. 1, Oxford University Press	
	A9	GNESUTTA et al., "The Serine/Threonine Kinase PAK4 Prevents Caspase Activation and Protects Cells from Apoptosis," <u>The Journal of Biological Chemistry</u> , April 27, 2001, pp. 14414-14419, Vol. 276, No. 17, The American Society for Biochemistry and Molecular Biology, Inc., USA	
	A10	HASHIMURA et al., "Production of Rabbit Antibody Specific for Amino-Terminal Residues of Cholecystokinin Octapeptide (CCK-8) by Selective Suppression of Cross-Reactive Antibody Response," <u>Journal of Immunological Methods</u> , 1982, pp. 375-387, Vol. 55, Elsevier Biomedical Press	
	A11	KRENDEL et al., "Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton," <u>Nature Cell Biology</u> , April 2002, pp. 294-301, Vol. 4, No. 4	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

JAN 05 2004

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Compleat if Known

Application Number	10/611,671
Filing Date	07/02/2003
First Named Inventor	Tod R. SMEAL
Group Art Unit	1642
Examiner Name	Unassigned

Sheet 2 of 3

Attorney Docket Number 034536-0407

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A12	MUSACCIO et al., "The PH domain: a common piece in the structural patchwork of signaling proteins," <u>Trends in Biochemical Sciences</u> , September 1993, pp. 343-348, Vol. 18, The International Union of Biochemistry and Molecular Biology and Elsevier Trends Journals	
	A13	NIMS et al., "Production of Hyperimmune Serum With Mature Rabbits," <u>Laboratory Animal Science</u> , 1973, pp. 391-396, Vol. 23, No. 3, American Association for Laboratory Animal Science, USA	
	A14	NOBES et al., "Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility," <u>Biochemical Society Transactions</u> , 654 <sup>th</sup> Meeting Leicester, August 1995, pp. 456-459, Vol. 23, No. 3	
	A15	O'SHEA et al., "The ins and outs of cell-polarity decisions," <u>Nature Cell Biology</u> , March 2000, pp. E39-E41, Vol. 2, No. 3	
	A16	PANDEY et al., "Cloning and characterization of PAK 5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain," <u>Oncogene</u> , 2002, pp. 3939-3948, Vol. 21, Nature Publishing Group	
	A17	QU et al., "Activated PAK4 Regulates Cell Adhesion and Anchorage-Independent Growth," <u>Molecular and Cellular Biology</u> , May 2001, pp. 3523-3533, Vol. 21, No. 10, American Society for Microbiology	
	A18	REDDY et al., "Isolation and Characterization of Complementary DNA to Proliferating Cell Nucleolar Antigen P40," <u>Cancer Research</u> , April 1, 1989, pp. 1763-1767, Vol. 49, No. 7, American Association for Cancer Research	
	A19	REN et al., "Cloning and Characterization of GEF-H1, a Microtubule-associated Guanine Nucleotide Exchange Factor for Rac and Tho GTPases," <u>The Journal of Biological Chemistry</u> , December 25, 1998, pp. 34954-34960, Vol. 273, No. 52, The American Society for Biochemistry and Molecular Biology, Inc.	
	A20	SATO et al., "Fluorescent indicators for imaging protein phosphorylation in single living cells," <u>Nature Biotechnology</u> , March 2002, pp. 287-294, Vol. 20, No. 3	
	A21	SHAMAH et al., "EphA Receptors Regulate Growth Cone Dynamics through the Novel Guanine Nucleotide Exchange Factor Ephexin," <u>Cell</u> , April 20, 2001, pp. 233-244, Vol. 105, Cell Press	
	A22	TAYLOR et al., "Nonradioactive Determination of Ras-GTP levels Using Activated Ras Interaction Assay," <u>Methods in Enzymology</u> , 2001, pp. 333-342, Vol. 333, Academic Press	
	A23	YANG et al., "Androgen Receptor Specifically Interacts with a Novel p21-activated Kinase, PAK6," <u>The Journal of Biological Chemistry</u> , May 4, 2001, pp. 15345-15353, Vol. 276, No. 18, The American Society for Biochemistry and Molecular Biology, Inc., USA	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Compl te if Known</b>
Sheet	3	of	3	Application Number: 10/611,671 Filing Date: 07/02/2003 First Named Inventor: Tod R. SMEAL Group Art Unit: 1642 Examiner Name: Unassigned Attorney Docket Number: 034536-0407

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.